جستجوی مقالات مرتبط با کلیدواژه « all-trans retinoic acid » در نشریات گروه « پزشکی »

The aryl hydrocarbon receptor (AHR) was identified for its mediating toxicological role in response to variety of the polycyclic aromatic hydrocarbon family of environmental contaminants however, recent data indicate that the AHR can be activated with different types of endogenous and exogenous chemicals. The aim of this study was to gain more information about the mechanisms that regulate expression of the AHR target gene, CYP1A1 by All-trans retinoic acid (ATRA) in human hepatoma cells (HepG2 and Huh7). The human hepatoma cell line (HepG2-XRE-Luc) carrying cytochrome P4501A1 (CYP1A1) response elements, HepG2 and Huh7 cells were exposed to different doses of ATRA (1-50 µM) and CYP1A1 transcription and enzymatic activities, as well as gene expression were measured. Our results showed that ATRA is able to induce CYP1A1 in an AHR-dependent manner using CH223191 as an AHR antagonist. The result showed that different doses of ATRA have no significant effects on cell viability.CYP1A1 enzyme and transcription activities as well as CYP1A1 mRNA for all treated group showed a significant elevation by ATRA. To better understand the mechanism underlying AHR activation by ATRA more molecular studies are needed. 

Several researcheshave proven that high levels of noise can induce oxidative stress and increase free radical's formation, particularly hydrogen peroxide (H2O2) and nitric oxide (NO) production. Retinoids are polyisoprenoid lipids derived from vitamin A or retinol. These molecules are essential regulatory elements in cell processes. All-trans retinoic acid (ATRA) plays a vital function in cellular growth, apoptosis, reproduction, cell differentiation, and immune feature by binding to its nuclear receptors.

In this study, we studied the protective effect of ATRA on H2O2-induced damage to bone marrow mesenchymal stem cell (BMSCs)-derived hair cells in culture.

Expression of MATH1 and SOX2 genes were assayed by immunocytochemistry (ICC). In order to evaluate the tolerance of ATRA-treated cells, after incubation of hair cells-like cells with ATRA, it was exposed to H2O2as an oxidative stress model. Then, the apoptosis percentage of cultivated hair cell-like cells was evaluated by acridin-orange staining method.

Our findings revealed that apoptotic cells were markedly diminished in the ATRA+H2O2co-treated cells in comparison with the H2O2 only–treated group.

ATRA has the protective effect against oxidative stress damage in the cultivated hair cells-like cells by reducing the apoptosis.

Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia (AML). APL is famed with some special blood coagulation disorders such as disseminated intravascular coagulation (DIC). The therapeutic methods of APL contain All Trans Retinoic Acid (ATRA), arsenic trioxide (ATO) or/and chemotherapy. Many studies have been done on APL blood disorders and its treatment. These studies have shown different results. In this systematic article, we tried to review the effect of ATO therapy with or without ATRA and chemotherapy on DIC parameters (D.dimer, Prothrombin Time, Activated Partial Thrombin Time, Platelet count) in APL patients. The result of included studies demonstrated that although ATO can reduce the number of malignant cells in the bone marrow and peripheral blood, it does not have enough potential to attenuate the danger of high score DIC that is usual in APL patients and should be better to be used with other therapeutic methods.

Developing chemotherapy with nanoplatforms offers a promising strategy for effective cancer treatment. In the present study, we propose a novel all-trans retinoic acid (ATRA) grafted poly beta-amino ester (PBAE) copolymer for preparing nanoparticles (NPs).

ATRA grafted PBAE (ATRA-g-PBAE) copolymer was synthesized by grafting ATRA to PBAE; it was characterized by proton nuclear magnetic resonance, Fourier transform infrared, and thermogravimetric analysis. ATRA-g-PBAE NPs were prepared by the solvent displacement method. Design-Expert software was employed to optimize size of NPs. The morphology was evaluated by transmission electron microscope, and ultraviolet-visible spectroscopy was applied for drug release. Cytotoxicity was evaluated toward HUVEC cell line, and the 3D collagencytodex model was used to evaluate anti-angiogenic property of PBAE, ATRA, and NPs.

The optimum size of the NPs was 139.4 ± 1.41 nm. After 21 days, 66.09% ± 1.39 and 42.14% ± 1.07 of ATRA were released from NPs at pH 5.8 and 7.4, respectively. Cell culture studies demonstrated antiangiogenic effects of ATRA-g-PBAE NPs. Anti-angiogenesis IC50 was 0.007 mg/mL for NPs (equal to 0.002 mg/mL of ATRA) and 0.005 mg/mL for free ATRA.

This study proposes the ATRA-g-PBAE NPs with inherent anti-angiogenic effects as promising carrier for anticancer drugs with purpose of dual drug delivery.

Acute promyelocytic leukemia represents a medical emergency with a high rate of early mortality. It has a high predilection for disseminated intravascular coagulation and in the absence of treatment, can be rapidly fatal. Without treatment, the median survival is less than 1 month.The coagulopathy in APL is complex and can be attributed to a combination of thrombocytopenia, disseminated intravascular coagulation and hyperfibrinolysis. White blood cell count at presentation is an important predictor of early hemorrhagic death. With the discovery of all-trans retinoic acid and arsenic trioxide, acute promyelocytic leukemia has transformed from a devastating disease into one of the most curable malignancies.Patients should be monitored for the development of differentiation syndrome, seen in 25 % of patients within 2-21 days of initiation of treatment. Early death is still a key issue, particularly in the elderly population, reiterating the importance of rapid diagnosis and treatment.We report the case of a 48 year-old-male diagnosed with the microgranular variant of acute promyelocytic leukemia M3 subtype and treated with all-trans retinoic acid and arsenic trioxide who achieved complete hematological remission.

Retinoid signaling has been argued to have favorable effects on Alzheimer's disease (AD). We studied the role of chronic intracerebroventricular (ICV) injection of all-trans retinoic acid (ATRA) on the amyloid-beta (Aβ) model of AD.
Adult male rats weighing 260-330 g were divided into 12 groups of 8 each. Six groups of rats received ATRA (3nM, 30nM, 3μM, 0.3mM, 30mM/rat; ICV) or DMSO 1% (2μl/rat; ICV), bilaterally and in a chronic manner (6 times, twice a week). Forty eight hours following the last injection, memory performance was assessed using a passive avoidance paradigm. One group received Aβ (10μg/rat; ICV), bilaterally. The control group received DMSO 1% (2μl/rat; ICV). Twenty days later memory performance was assessed. Three groups of rats received Aβ (10μg/rat; ICV) and then ATRA (3nM or 30nM/rat; ICV) or DMSO 1%, chronically (6 times, twice a week). Another group received DMSO 1% (2μl/rat; ICV) and then, DMSO 1%, chronically (6 times, twice a week).
ATRA at doses 0.3mM and 30mM/rat impaired memory retrieval by decreasing step-through latency (STL) and increasing time spent in the dark compartment (TDC), significantly. However, moderate doses (3nM and 30nM/rat) did not change memory performance. ATRA (30nM/rat) increased STL and decreased TDC and NST in the Aβ-treated rats, significantly compared to the group received Aβ-DMSO 1%.
The results propose a potential prophylactic effect of ATRA in the ICV Aβ model of AD and indicate the prominence of retinoic acid signaling as a target for AD prevention.